Medimaps Group Appoints Meinhard F. Schmidt as Board Chairman; Adds Anne Le Grand and Five Additional Board Members
Medimaps Group (www.medimapsgroup.com), a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand, an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221128005146/en/
Medimaps Group Announces Board Members: Meinhard F. Schmidt as Board Chairman, and Anne Le Grand Plus Five Other Members and One Strategic Advisor. (Photo: Business Wire)
Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise. Visit Medimaps website for information about the entire Medimaps Group board and leadership team.
“I’m pleased to welcome Meinhard and Anne to our Board of Directors,” said Prof. Didier Hans, Ph.D., MBA, Chief Executive Officer and Board Member of Medimaps Group. “Meinhard’s global leadership roles in diagnostics at Philips and Roche Diagnostics—and Anne’s work leading medical imaging and healthcare businesses including AI solutions—offer Medimaps significant expertise and acumen to support our immediate growth and shape our future success.”
About the Appointees:
- Mr. Schmidt held senior leadership roles at Philips and Roche Diagnostics where he held various global senior leadership roles in Patient/Diabetes-Care, Laboratory- and PoC-Diagnostics. After that he worked as an executive at Institute Straumann as a Business Unit head and then CEO, where he was responsible for their digital group for the worldwide “Digitalization” of the Dental industry. Currently he holds board and advisory roles for public and private MedTech/Digital Health companies, focusing on growth and commercialization.
- Ms. Le Grand served as global Vice President IBM and General Manager for Watson Health Imaging, Oncology, Genomics and Life Sciences. Prior to IBM, she held executive leadership positions at Philips Health Systems, leading the Therapeutic Care and Ultrasound divisions. Prior to that Ms. Le Grand served as SVP Healthcare of Global X-ray for GE Healthcare, where she successfully launched and refreshed portfolios across the global x-ray, mammography, and metabolic bone disease businesses. She currently holds board and consulting roles for public and private sector healthcare companies.
Additional board members include:
- Robert Schier, Ph.D., Senior Investment Director at Zürcher Kantonalbank Asset Management (Swisscanto Private Equity). Dr. Schier sits on the Boards of Directors of many life sciences companies. He holds a degree in pharmacy from the University of Vienna and a Ph.D. in biotechnology from the University of Natural Resources and Life Sciences, Vienna.
- Myoung-Ok Kwon, Ph.D., investment partner at Swisscom and leading digital health investments. She has 20 years of experience in healthcare investment and pharma research. At Novartis, she was responsible for research strategy and planning and portfolio review. She holds a Ph.D. in biochemistry and molecular genetics from the Friedrich Miescher Institute, Novartis, and the University of Basel.
- Georgette Schmid, investment manager at Helvetica Capital AG. Prior to joining Helvetica Capital, Mrs. Schmid was working in the business development and investment division within the consumer goods and hotel industry. She holds a Master of Law from the University of Zurich and a Master of Business Administration (MBA) from Ecole hôtelière de Lausanne.
- Prof. Didier Hans, Ph.D., MBA, who has been CEO of Medimaps Group since 2012. He has 25+ years of experience in dual-energy x-ray absorptiometry (DXA), bone macro- and microarchitecture, ultrasound imaging techniques, and body composition assessment. He teaches worldwide on bone and body composition imaging and osteoporosis. He holds a Ph.D. in medical physics and an Executive MBA from HEC Geneva.
- Sarah Lumb, co-founder and managing partner of Mission Global, a freight specialist in event logistics. She played an integral part in the creation of the group, now with nearly 200 partner offices worldwide. Her business interests extend to two other companies–Ethical Pharmaceutical Consulting Service SA and Kanis SA–that have investments across a diverse range of industries, but with a particular interest in biotech, medical device, and other high-technology companies.
- Lauren Nicola, MD (board advisor), CEO of Triad Radiology Associates in the U.S., where she is subspecialized in breast imaging and pediatric radiology. A national health policy expert, Dr. Nicola holds leadership positions at the American College of Radiology, including the chair of the Reimbursement Committee and the Medicare Access and Chip Reauthorization Act (MACRA) committee. She has been instrumental in the creation and valuation of multiple new imaging and AI codes. She holds a medical degree from Duke University School of Medicine in North Carolina, U.S.
About Medimaps Group
Medimaps Group’s medical imaging software applications based on patented multi-purpose technology with artificial intelligence capabilities provide healthcare solutions that fit seamlessly into the workflow for the benefit of the patient. TBS iNsight™ (Osteo) has been used for years in clinical practice worldwide in the field of osteoporosis. It has become the new gold standard for bone texture assessment in routine clinical practice. TBS has gained international recognition with more than 900 peer-reviewed scientific publications and is included in many guidelines and used by more than 30,000 physicians worldwide including leading healthcare institutions. Learn more at https://www.medimapsgroup.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005146/en/
Contact information
Shelley Horn
+1 240 994 0248
shorn@medimapsgroup.com
Robert Minicucci
+1 339 206 1722
rminicucci@ramhealthcomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release
Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release
Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release
4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom